StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a report released on Sunday morning. The brokerage issued a hold rating on the medical equipment provider’s stock.

IRIDEX Trading Down 1.2 %

Shares of NASDAQ:IRIX opened at $1.61 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The stock has a market capitalization of $26.83 million, a price-to-earnings ratio of -2.41 and a beta of 0.82. IRIDEX has a 1-year low of $1.27 and a 1-year high of $3.65. The company has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.81.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The company had revenue of $11.58 million for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. During the same period last year, the company posted ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.